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Abstract
 
Mice deficient for the transcriptional coactivator BOB.1/OBF.1 show several defects in B cell
differentiation. Numbers of immature transitional B cells in the bone marrow are reduced and
fewer B cells reach the periphery. Furthermore, germinal center B cells are absent and marginal
zone (MZ) B lymphocytes are markedly reduced. Increased levels of B cell apoptosis in these
mice prompted us to analyze expression and function of antiapoptotic proteins. Bcl2 expression
is strongly reduced in BOB.1/OBF.1-deficient pre–B cells. When BOB.1/OBF.1-deficient
mice were crossed with Bcl2-transgenic mice, B cell development in the bone marrow and
numbers of B cells in peripheral lymphoid organs were normalized. However, neither germinal
center B cells nor MZ B cells were rescued. Additionally, Bcl2 did not rescue the defects in sig-
naling and affinity maturation found in BOB.1/OBF.1-deficient mice. Interestingly, Bcl2-
transgenic mice by themselves show an MZ B cell defect. Virtually no functional MZ B cells
were detected in these mice. In contrast, mice deficient for Bcl2 show a relative increase in MZ
B cell numbers, indicating a previously undetected function of Bcl2 for this B cell compartment.
 
Key words: B cell differentiation • germinal center reaction • afﬁnity maturation • marginal zone • 
transcription factor
 
Introduction
 
BOB.1/OBF.1 (Bob.1, OBF-1, or OCA-B; references 1–4)
is a B cell–specific transcriptional coactivator. It interacts
with the Oct1 and Oct2 transcription factors and augments
their function. BOB.1/OBF.1 is expressed at all stages of B
cell development, albeit at different expression levels. High-
est BOB.1/OBF.1 expression was found in germinal center
B cells and germinal center–derived B cell lymphomas (5,
6). Expression levels are regulated both by transcription as
well as protein stability (7, 8). In T cells, expression of func-
tional BOB.1/OBF.1 is inducible by costimulation (9). A
myristylated BOB.1/OBF.1 protein isoform exists that is
localized in the membrane fraction (10).
Inactivation of BOB.1/OBF.1 by gene targeting re-
vealed its critical role for B lymphopoiesis. BOB.1/
OBF.1-deficient mice completely lack germinal centers
upon immunization with thymus-dependent antigens.
Consequently, these mice fail to mount a strong immune
response with secondary Ig-isotypes (11–13). In addition, a
virtually identical phenotype was observed in mice lacking
the Oct2 transcription factor (14). Although early B lym-
phopoiesis still occurs, BOB.1/OBF.1 is also critical for the
formation of immature transitional B cells in the bone mar-
row (15). BOB.1/OBF.1-deficient mice lack marginal
zone (MZ) B lymphocytes, whereas the B1 B cell com-
partment is apparently unaffected (16). The observed re-
duction of B cell numbers in bone marrow and spleen of
BOB.1/OBF.1-deficient mice could have two reasons: the
generation of B cells could be affected or alternatively,
the B cells generated might undergo apoptosis. Indeed,
BOB.1/OBF.1-deficient B cells show increased levels of
apoptosis (15).
Here, we show that expression levels of Bcl2 in pre–B
cells from BOB.1/OBF.1-deficient mice were reduced
compared with wild-type mice. When BOB.1/OBF.1
 
 
 
/
 
 
 
mice were crossed with Bcl2-transgenic mice, several de-
fects such as absolute B cell numbers and the maturation
state in bone marrow and spleen were rescued. However,
Bcl2 failed to rescue MZ B cells, cell signaling, and the ger-
minal center reaction.
 
Address correspondence to Thomas Wirth, Dept. of Physiological
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Materials and Methods
 
Mice.
 
Wild-type mice, BOB.1/OBF.1
 
 
 
/
 
 
 
, Bcl2-22 trans-
genic (Bcl2 tg), Bcl2
 
 
 
/
 
 
 
 (17), or Bcl tg 
 
 
 
 BOB.1/OBF.1
 
 
 
/
 
 
 
mice (C57BL/6 background) were obtained from our breeding
facility. Mice were analyzed at 8–12 wk.
 
Protein Immunoblots and RNase Protection Assay.
 
Western blot
analyses were performed as described previously (16) with mono-
clonal mouse Bcl2- or RelA-specific polyclonal antibodies (Santa
Cruz Biotechnology, Inc.). RNase protection assays were per-
formed with the kit provided by Becton Dickinson with the
mApo2 multi-probe template set.
 
FACS
 
®
 
 Analysis.
 
FACS
 
®
 
 analyses (16) were performed with
the following antibodies: anti–B220-biotin, anti–CD21-FITC,
anti–CD23-PE, anti–IgM-PE, anti–IgD-biotin, anti–CD1-
FITC, anti–B220-PerCP, and anti–TNP-biotin (BD Bio-
sciences). Biotin-labeled antibodies were revealed by streptavi-
din–Cy-Chrome or streptavidin-APC (BD Biosciences). Surface
marker expression was analyzed with a four-color FACSCali-
bur™ and CELLQuest™ software (Becton Dickinson). Calcium
influx into B220
 
 
 
 cells was analyzed as described previously
(16). B220
 
 
 
 cells were sorted with FACsort™ plus cytometer
(Becton Dickinson).
 
Determination of Serum Antibodies and Immunizations.
 
Serum
Ig titers were determined in serial dilutions by ELISA with iso-
type-specific goat anti-Ig–coated plates (Southern Biotechnology
Associates, Inc.), goat anti-Ig alkaline phosphatase–linked anti-
bodies, and the substrate 
 
p
 
-nitrophenyl phosphate (Sigma-
Aldrich). Mouse Igs of various isotypes (Southern Biotechnology
Associates, Inc.) were used as internal standards.
Mice were immunized intraperitoneally with 100 µg TNP
 
13
 
-
OVA (Biosearch Technologies), preincubated in Alu-Gel-S
(Serva) at day 0, boosted at day 14, and the ELISA with TNP
 
14
 
-
BSA was performed as described previously (18).
For affinity measurements, sera of each day and each group of
mice were pooled and ELISAs with TNP
 
3
 
-BSA– and TNP
 
14
 
-
BSA–coated plates were done. Ratios of TNP
 
3
 
-BSA–binding
and TNP
 
14
 
-BSA–binding antibodies were calculated for each
time point.
Mice were injected intravenously with 100 µg TNP-Ficoll
(Biosearch Technologies). After 30 min, spleens were taken and
used for histology and FACS
 
®
 
 analysis.
 
Histological Analyses.
 
Spleen sections were stained as described
previously (16) with anti–IgM-PE (BD Biosciences) and
MOMA-1–FITC (Serotec) or IgM-PE and IgD-FITC antibodies
(BD Biosciences). Sections from TNP-Ficoll–treated animals
were stained with a combination of anti–TNP-biotin (BD Bio-
sciences) and MOMA-1–FITC antibodies. Biotinylated antibod-
ies were revealed with streptavidin–Cy-Chrome (BD Biosciences).
Nuclei were stained with DAPI (Roche). Germinal centers were
visualized using PNA-biotin (Vector Laboratories; reference 19).
OpenLab software (Improvision) was used for analysis.
 
Results and Discussion
 
Reduced Bcl2 Expression in BOB.1/OBF.1-deficient pre–B
Cells.
 
We noted previously a higher level of B cell apop-
tosis in BOB.1/OBF.1-deficient mice (15). Therefore, we
analyzed the expression of pro- and antiapoptotic genes in
BOB.1/OBF.1-deficient B cells. Bone marrow pre–B cell
lines continuously growing in the presence of IL-7 plus
stroma cells were established from wild-type and mutant
mice to analyze cells of the same differentiation stage for
the two genotypes (20; unpublished data). RNA was ana-
lyzed for expression of apoptosis-related genes. Interest-
ingly, expression levels for Bcl2 were reduced in BOB.1/
OBF.1-deficient pre–B cells (Fig. 1 A). This result was
confirmed in protein immunoblots (Fig. 1 B). To analyze
Bcl2 expression in mature peripheral B cells, B220
 
 
 
 cells
were sorted from spleens of either wild-type or BOB.1/
OBF.1-deficient mice. This analysis did not reveal signifi-
cant differences in the expression levels of Bcl2 (Fig. 1 C).
Therefore, the regulation of Bcl2 by BOB.1/OBF.1 is
stage-dependent and most likely indirect.
 
B Cell–specific Expression of Bcl2 Rescues B Cell Numbers in
Bone Marrow and Spleen.
 
In the bone marrow, BOB.1/
OBF.1-deficient mice show reduced numbers of transitional
B cells and recirculating B cells. In the spleen, numbers of B
cells are reduced, especially in the long-lived IgM
 
low
 
/IgD
 
high
 
population. We asked whether these defects could be cor-
rected by transgenic expression of Bcl2. BOB.1/OBF.1
 
 
 
/
 
 
 
mice were crossed with mice expressing the Bcl2 transgene
in B cells (21). Expression of Bcl2 by itself resulted in an in-
crease of B cell numbers in the bone marrow and spleen of
wild-type mice (Table I). Importantly, the reductions of B
cell numbers observed in BOB.1/OBF.1-deficient mice
were rescued both in the bone marrow as well as in the
spleen (Table I). Numbers of all affected B cell populations
were higher than in wild-type mice and approached num-
bers observed in the Bcl2 single transgenic mice. The in-
creased ratio of apoptotic B lymphocytes was also corrected
(Table I). These results demonstrate that forced expression
of Bcl2 is sufficient to regenerate both normal numbers as
Figure 1. Impaired Bcl2 expression in bone marrow–derived IL7-
dependent pre–B cells of BOB.1/OBF.1-deficient mice. (A) RPA was
performed with 20 µg of total RNA prepared from pre–B cell lines of the
indicated genotype and the murine Apo2 multi-probe template set. (B
and C) Western blots were performed with antibodies specific for Bcl2
and, as a control, RelA. (B) 50 µg of protein extracts from IL-7–depen-
dent bone marrow pre–B cell lines established from BOB.1/OBF.1 /  or
 /  mice. (C) Protein extracts from 106 B220  sorted splenocytes.T
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well as a normal cell surface phenotype of B lymphoid cells
in BOB.1/OBF.1-deficient mice.
 
Bcl2 Does Not Rescue Defective Immune Responses and Ger-
minal Center Reactions.
 
BOB.1/OBF.1 is important for an-
tigen-dependent B cell responses (11–13). To analyze
whether antibody responses were rescued by Bcl2 expres-
sion, we determined levels of serum immunoglobulins. Bcl2-
transgenic wild-type mice showed increased serum immuno-
globulin levels of all isotypes compared with controls.
Although immunoglobulin levels in Bcl2 tg 
 
 
 
 BOB.1/
OBF.1
 
 
 
/
 
 
 
 mice were increased compared to knockout
mice, they failed to reach wild-type levels (Fig. 2 A). This in-
dicates that increased numbers of peripheral B cells resulted
in only a partial rescue of immunoglobulin production.
We examined the antigen-specific T cell–dependent
immune responses against TNP-OVA. Immunization of
wild-type and Bcl2-transgenic mice led to a strong anti-
TNP IgG1 production. In contrast, BOB.1/OBF.1-defi-
cient mice showed only weak primary and secondary IgG1
responses, which were only partially corrected in tgBcl2/
BOB.1/OBF.1
 
 
 
/
 
 
 
 mice (Fig. 2 B). IgG1 production after
21 d and secondary restimulation in the tgBcl2/BOB.1/
OBF.1
 
 
 
/
 
 
 
 animals was significantly increased, but still
 
 
 
10-fold lower than in wild-type mice. Given the two- to
threefold higher numbers of B cells in tgBcl2/BOB.1/
OBF.1
 
 
 
/
 
 
 
 compared with wild-type mice, this indicates a
profound defect in immunoglobulin production.
We wondered whether these mice did perform affinity
maturation or whether increased Ig-levels represented an
enhanced primary response. ELISAs were performed with
sera of TNP-OVA–immunized mice with TNP
 
3
 
-BSA–
and TNP
 
14
 
-BSA–coated plates. The ratio of low epitope
 
Table I.
 
B cell–specific Transgenic Expression of Bcl2 Rescues B Cell Numbers and Maturation Phenotypes in Bone Marrow and Spleen of 
BOB.1/OBF.1-deficient Mice
 
Wild type Bcl2 tg BOB.1/OBF.1 ko Bcl2 tg 
 
 
 
 BOB.1/OBF.1 ko
Absolute cell number 
 
 
 
 10
 
7
 
Spleen
Total cellularity 9.0 
 
 
 
 0.7 22.3 
 
 
 
 2.2 6.2 
 
 
 
 1.2  21.7 
 
 
 
 1.6 
B220
 
 
 
5.5 
 
 
 
 0.9 16.8 
 
 
 
 1.3 2.3 
 
 
 
 0.3 14.5 
 
 
 
 2.5
T1 1.8 
 
 
 
 0.3 4.6 
 
 
 
 0.5 1.1 
 
 
 
 0.1 6.1 
 
 
 
 0.6
T2 1.9 
 
 
 
 0.3 5.6 
 
 
 
 0.9 0.6 
 
 
 
 0.1 3.7 
 
 
 
 1.3
M 1.8 
 
 
 
 0.3 5.7 
 
 
 
 0.7 0.6 
 
 
 
 0.1 3.8 
 
 
 
 1.1
Annexin V
 
 
 
/B220 0.46 
 
 
 
 0.24 0.89 
 
 
 
 0.29 0.25 
 
 
 
 0.08 1.22 
 
 
 
 0.59
Bone marrow
Total cellularity 2.3 
 
 
 
 0.4 3.3 
 
 
 
 1.1 2.0 
 
 
 
 0.7 2.7 
 
 
 
 0.9
Pro/Pre B 0.54 
 
 
 
 0.06 0.61 
 
 
 
 0.08 0.64 
 
 
 
 0.15 0.64 
 
 
 
 0.15
Immature 0.32 
 
 
 
 0.08 0.89 
 
 
 
 0.14 0.33 
 
 
 
 0.14 0.92 
 
 
 
 0.09
Transitional 0.12 
 
 
 
 0.02 0.31 
 
 
 
 0.11 0.04 
 
 
 
 0.01 0.16 
 
 
 
 0.05
Recirculating 0.23 
 
 
 
 0.06 0.57 
 
 
 
 0.16 0.06 
 
 
 
 0.04 0.26 
 
 
 
 0.06
 
%% % %
 
Spleen
B220
 
 
 
61.9 
 
 
 
 9.7 75.3 
 
 
 
 5.7 36.7 
 
 
 
 5.2 66.6 
 
 
 
 11.4
T1 20.4 
 
 
 
 2.9 20.8 
 
 
 
 2.2 16.9 
 
 
 
 1.6 27.9 
 
 
 
 2.7
T2 21.0 
 
 
 
 5.8 24.9   3.9 10.0   1.1 17.1   6.1
M 19.4   3.6 25.4   3.3 9.1   2.0 17.6   4.9
Annexin V /B220 8.3   4.3 5.3   1.7 10.7   3.4 8.4   4.1
Bone marrow
Pro/Pre B 23.3   2.5 18.6   2.5 32.2   7.3 23.7   5.6
Immature 14.0   3.4 26.9   4.3 16.4   7.2 34.1   3.2
Transitional 5.1   0.6 9.5   3.4 1.8   0.5 5.8   1.8
Recirculating 10.0   2.7 17.2   5.0 3.2   2.1 9.5   2.2
The total cell numbers per spleen or femur from animals at 8–9 wk of age of each genotype were determined. Before analyses splenic cells were
purified by Ficoll gradient. Bone marrow cells were stained with a combination of anti-B220 and anti-IgM antibodies to discriminate between pro/
pre–B cells, immature, transitional and recirculating B cells. Splenocytes were stained with a mixture of anti-B220, anti-IgM, and anti-IgD antibodies
to distinguish between the IgMhighIgDlow (T1), IgMhighIgDhigh (T2), and IgMlowIgDhigh (M) populations and to determine the overall B cell numbers.
Additionally, splenocytes were stained with a mixture of anti-B220 and anti–Annexin V antibodies. Mean percentages as well as absolute numbers
for B cells of each compartment with standard deviation out of six to eight animals of each genotype are given.T
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(TNP3) to high epitope (TNP14) binding of antibodies is
proportional to their relative affinities, and affinity matura-
tion can be measured in this way (22). Both wild-type and
Bcl2-transgenic mice showed affinity maturation during
primary and secondary responses (Fig. 2 C). Affinity matu-
ration was completely absent in BOB.1/OBF.1-deficient
mice and present at only low levels after secondary immu-
nization in Bcl2 tg   BOB.1/OBF.1 /  mice. These re-
sults show for the first time a complete lack of affinity mat-
uration in BOB.1/OBF.1 /  mice, a defect that cannot be
rescued by expression of Bcl2.
After immunization with TNP-OVA, mice were ana-
lyzed for the formation of germinal centers. Staining of
spleen sections with PNA revealed germinal centers in
wild-type and Bcl2 tg mice. However, no germinal centers
were detectable in BOB.1/OBF.1-deficient mice and Bcl2
tg   BOB.1/OBF.1-deficient mice (Fig. 2 D).
We had shown previously that Ca2  influx after IgM
stimulation is reduced in BOB.1/OBF.1-deficient B cells
(16, 18). This defect is barely corrected by the Bcl2 trans-
gene (Fig. 3). On a wild-type background, Bcl2 expression
also resulted in slightly increased BCR signaling. These re-
sults indicate that transgenic Bcl2 does not efficiently rescue
B cell functions, such as BCR signaling, Ig production, and
affinity maturation. They require the presence of BOB.1/
OBF.1. For the progression of pre–B cells to immature and
mature B cells, competent signaling of the BCR is needed
(23). In BOB.1/OBF.1 /  mice, transition from pro– to
pre–B cells is not affected (15). Therefore, pre-BCR signal-
ing might not be affected in BOB.1/OBF.1-deficient cells.
In adult mice, Bcl2 is found in the pro- and pre–B cell
stages, then at lower levels throughout the immature B cell
stage, and finally at higher levels in the mature IgD  B cells
(24). Bcl2 expression is diminished or absent in germinal
centers (25, 26). Down-regulation of Bcl2 occurs at stages
and sites associated with extensive apoptosis combined with
powerful selection processes of B cells undergoing produc-
tive assembly of IgH and IgL chains or somatic hypermuta-
tions of their V region genes (26). Expression of Bcl2 in
BOB.1/OBF.1-deficient B cells may result in impaired
positive or negative selection processes during B cell matu-
ration and consequently in an accumulation of B cells bear-
ing either nonreactive or autospecific antigen receptors.
Bcl2 Does Not Rescue MZ B Cell Compartment in BOB.1/
OBF.1 /  Mice. MZ B cells represent a distinct subset of
effector B lymphocytes. They are exclusively located in the
spleen, at the border between white and red pulp (27). In
addition to the requirement of BOB.1/OBF.1 for germinal
center formation, the MZ B cell compartment is also af-
fected in BOB.1/OBF.1-deficient mice (16). We asked
whether transgenic Bcl2 expression could rescue this de-
Figure 2. Bcl2 fails to rescue defective T cell–dependent immune re-
sponses in BOB.1/OBF.1-deficient mice. (A) Mice (age 10–12 wk) were
bled and Ig levels determined by ELISA. Each symbol represents one in-
dividual mouse. (B) Analyses of IgG1 responses in TNP-OVA–immu-
nized mice (age 10–12 wk). Each symbol represents one individual
mouse. Arrows indicate days of TNP-OVA injection. (C) Sera of immu-
nized mice (B) were pooled and assayed for TNP3-BSA–binding and
TNP14-BSA–binding. The ratio of TNP3- to TNP14-binding is propor-
tional to the affinity of the TNP-specific antibodies. (D) Spleen sections
from TNP-OVA–immunized animals (day 14) stained with biotinylated
PNA. Binding of PNA to germinal centers is visualized using streptavi-
din-HRP and AEC compound as a substrate. Sections were counter-
stained with hematoxylin.
Figure 3. Bcl2 does not rescue
impaired Ca2  influx in response
to IgM cross-linking. Calcium
influx upon BCR stimulation
into splenic B cells (B220 ) from
wild-type, BOB.1/OBF.1 / ,
Bcl2 tg, and Bcl2 tg   BOB.1/
OBF.1 /  (A) or wild-type and
Bcl2 /  mice (B) was monitored
by flow cytometry. Data are rep-
resentative for four independent
experiments. IgM levels per cell
were comparable between all an-
alyzed genotypes (not depicted).T
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fect. B220  splenocytes were stained for CD21 and CD23
to discriminate between newly formed (transitional;
CD21lowCD23low), follicular (CD21intCD23high), and MZ
B cells (CD21highCD23low). The MZ B cell population was
not only absent in BOB.1/OBF.1-deficient mice (16) but
also in wild-type mice expressing the Bcl2 transgene (Fig. 4
A). Consequently, this population was also absent in Bcl2
tg   BOB.1/OBF.1 /  mice (Fig. 4 A). Identical results
were obtained when we checked for CD1high cells among
IgMhigh/IgDlow cells, which are also markers of MZ B cells
(unpublished data).
To exclude the possibility that absent MZ B cells in
Bcl2-transgenic mice might be a consequence of misex-
pression of cell surface markers, we performed immunohis-
tochemical examinations of spleens. The MOMA-1 anti-
body, specific for metallophilic macrophages, demarcates
the border between MZ and follicle (27). The characteris-
tic rim of IgM-positive MZ B cells was lacking in sections
from BOB.1/OBF.1 /  mice (Fig. 4 B). Although IgM-
positive cells could be detected in Bcl2 tg as well as in Bcl2
tg   BOB.1/OBF.1 /  mice, these cells also stained posi-
tive for IgD (Fig. 4 C). Because MZ B cells show only low
levels of IgD and a high level of IgM (27, 28), this result
suggests that cells outside of the MOMA-1 rim in the
spleens of Bcl2-transgenic and Bcl2 tg   BOB.1/OBF.1 / 
mice are not typical MZ B cells.
MZ B cells will rapidly capture intravenously injected
antigens such as TNP-Ficoll. We injected mice with TNP-
Ficoll and analyzed binding by FACS® and immunohis-
tochemical analysis. In wild-type mice, TNP-Ficoll was
exclusively bound by CD21highCD23low MZ B cells (16;
unpublished data), which were exclusively localized outside
the metallophilic macrophage rim (Fig. 4 D). No TNP-
Ficoll–capturing B cells were seen in BOB.1/OBF.1 / 
mice, and only low numbers in Bcl2-transgenic or Bcl2
tg   BOB.1/OBF.1 /  mice were seen by FACS® (un-
published data). In the latter cases, no TNP-Ficoll–captur-
ing cells outside the rim of MOMA-staining were detected
(Fig. 4 D). Therefore, these B cells cannot be considered
functional MZ B cells.
The MZ is a complex structure consisting of a stromal
cell framework in which specialized B cells, macrophages,
and APCs interact. We performed a detailed analysis of the
MZ structure to investigate whether the observed alter-
ations of MZ B cells correlated with changes in the general
MZ structure. Splenic follicles were properly developed in
all mouse lines as judged by analyses of reticular fibroblasts
and MZ macrophages, recognized by the ER-TR7 and
Figure 4. Bcl2 does not rescue
marginal zone (MZ) B cell com-
partment in BOB1/OBF.1 / 
mice. (A) Splenocytes from mice
of the indicated genotypes were
stained with a combination of
antibodies specific for B220,
CD21, and CD23. Newly
formed (NF), follicular (FO),
and MZ B cells are indicated.
Mean percentages for MZ B cells
with standard deviation (four an-
imals each) are given. (B) Spleen
sections from indicated geno-
types were stained with antibod-
ies recognizing IgM (PE/red)
and MOMA-1 (FITC/green) or
(C) IgM (PE/red) and IgD
(FITC/green). (D) Spleen sec-
tions from TNP-Ficoll–immu-
nized animals were stained with
biotin-labeled anti-TNP (red)
and FITC-labeled anti–MOMA-1
(green) antibodies. Nuclei were
stained with DAPI (blue).T
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ER-TR9 antibodies (16; unpublished data). Therefore, the
observed alterations of the MZ B cell compartment in
BOB.1/OBF.1 /  and Bcl2-transgenic mice are not due to
general changes in MZ architecture.
The MZ B Cell Population of Bcl2-deficient Mice Is En-
larged. The finding that Bcl2-transgenic mice have a
reduced MZ B cell population could indicate that overex-
pression of Bcl2 is incompatible with a MZ B cell pheno-
type. Therefore, we investigated the MZ B cell population
in Bcl2-deficient mice (17). We found a twofold increase
in the number of MZ B cells, indicating that expression
levels of Bcl2 affect the MZ B cell compartment (Figs. 4, A
and B). Staining of histological sections of Bcl2-deficient
mice revealed an enlarged IgM  B cell population outside
the follicles. Several models are entertained regarding the
generation of MZ B cells. Recent findings suggested that
strong B cell receptor–derived signals block MZ B cell
development (19, 29), whereas weak signals favor their dif-
ferentiation. Consistent with this hypothesis, BCR cross-
linking–induced Ca2  influx was slightly decreased in Bcl2-
deficient B cells compared with wild-type cells, whereas
the signal was higher in Bcl2-transgenic B cells (Fig. 3 B).
These observations could explain the altered MZ B cell
populations in Bcl2-deficient and Bcl2-transgenic animals.
Alternatively, the lineage decision of transitional B cells
into MZ or follicular B cells may depend on the survival
rate. Slower B cell turnover in Bcl2-transgenics may favor
survival of follicular versus MZ B cells. Alternatively, due
to the increased B cell numbers in the spleen, B cells with
follicular phenotype (IgMlowIgDhigh) may fill up other
spaces than usual, displacing the MZ B cells from their
usual location, which indeed was detected in spleen histol-
ogy (Fig. 4 C). MZ B cells require the expression of LFA-1
and  4 1 integrins for their specific localization (30). Bcl2
might influence the presence and/or function of integrins
or chemokines, which are necessary for compartmentaliza-
tion of MZ B cells. Together, these findings indicate an
important role of Bcl2 during B cell maturation.
In summary, we have demonstrated a dependence of
Bcl2 expression on BOB.1/OBF.1 in pre–B cells. This
could explain the higher rate of apoptosis of early BOB.1/
OBF.1-deficient B cells. The expression of Bcl2 in
BOB.1/OBF.1-deficient B cells rescued their numbers and
the maturation phenotype but not their function. This in-
dicates a fundamental and complex role of BOB.1/OBF.1
in B cells independent of cell survival.
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